Myriad Genetics (NASDAQ:MYGN – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Valuation and Earnings
This table compares Myriad Genetics and Apogee Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Myriad Genetics | $824.50 million | 0.67 | -$365.90 million | ($4.30) | -1.37 |
| Apogee Therapeutics | N/A | N/A | -$255.84 million | ($4.33) | -30.61 |
Profitability
This table compares Myriad Genetics and Apogee Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Myriad Genetics | -48.24% | -8.51% | -4.48% |
| Apogee Therapeutics | N/A | -32.64% | -31.25% |
Insider & Institutional Ownership
99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Myriad Genetics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Myriad Genetics and Apogee Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Myriad Genetics | 1 | 4 | 1 | 0 | 2.00 |
| Apogee Therapeutics | 1 | 15 | 4 | 1 | 2.24 |
Myriad Genetics currently has a consensus target price of $6.50, suggesting a potential upside of 10.54%. Apogee Therapeutics has a consensus target price of $121.25, suggesting a potential downside of 8.52%. Given Myriad Genetics’ higher possible upside, research analysts plainly believe Myriad Genetics is more favorable than Apogee Therapeutics.
Summary
Myriad Genetics beats Apogee Therapeutics on 8 of the 14 factors compared between the two stocks.
About Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
About Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
